Gerçek Yaşamda PIK3CA Mutasyonları ile Alpelisib'in Etkinlik ve Tolere Edilebilirlik Sonuçlarının Çalışması

Sade dilde özet

Bu gerçek yaşam çalışması, PIK3CA mutasyonu taşıyan hormon reseptörü pozitif, HER2-negatif ileri/metastatik meme kanseri (breast cancer) hastalarında Alpelisib artı Fulvestrant tedavisinin etkinlik ve tolere edilebilirlik sonuçlarını incelemiştir. Çalışmaya, 18 yaş ve üzeri, ileri veya metastatik meme kanseri tanısı doğrulanmış hastalar alınmıştır. Faz uygulanmayan bu çalışma yürütülmüş ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

N/A

Durum

Tamamlandı

Sponsor

Novartis Pharmaceuticals

Müdahale

alpelisib plus fulvestrant

Başlangıç

27.10.2021

Tahmini bitiş

11.02.2025

Ülkeler

India

İlgili genler

Merkezler

• Hyderabad, India
• Guwahati, India
• Kochi, India
• Bhopal, India
• Mumbai, India
• Mumbai, India
• Nagpur, India
• Nagpur, India
• Pune, India
• New Delhi, India
• New Delhi, India
• Bhubaneswar, India
• Bhubaneswar, India
• Chandigarh, India
• Ludhiana, India
• Jaipur, India
• Sherilingampally, India
• Howrah, India
• Kolkata, India
• Kolkata, India
• Kolkata, India
• Ahmedabad, India
• Kanpur, India
• Kolkata, India
• Kolkata, India
• Kolkata, India
• Puducherry, India
• Udaipur, India

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

PART A:

1. Males (≥18 years of age), post-menopausal\* females or pre-menopausal\*\* females with ovarian ablation (as per physician decision).
2. Patients with confirmed diagnosis of ABC/MBC (locoregionally recurrent not amenable to curative therapy or metastatic)
3. Patient with histologically and/or cytologically confirmed diagnosis of HR-positive (ER+ and/or PgR+), as well as HER2-negative breast cancer by local laboratory (HER2- by Immunohistochemistry \[IHC\], for borderline2+ Fluorescence In Situ Hybridization \[FISH\])
4. A separate signed patient ICF for Part A of the study must be obtained prior to any data collection and sample shipment to the central designated laboratory
5. Patient's tumor tissue (archival or fresh) is available to be sent to a central laboratory for PIK3CA testing. In case, tissue sample (archival or fresh) is not available or feasible, liquid biopsy may be allowed.

PART B:

1. Males (≥18 years of age), post-menopausal\* females or pre-menopausal\*\* females with ovarian ablation (as per physician decision).
2. Patients with confirmed diagnosis of ABC/MBC (locoregionally recurrent not amenable to curative therapy or metastatic) - for direct enrollment patients into Part B of the study.
3. Patient with histologically and/or cytologically confirmed diagnosis of HR-positive (ER+ and/or PgR+), as well as HER2-negative breast cancer by local laboratory (HER2- by Immunohistochemistry \[IHC\], for borderline2+ Fluorescence In Situ Hybridization \[FISH\]) - for direct enrollment patients into Part B of the study.
4. Participants with confirmed positive PIK3CA mutation status prior to study entry.
5. A separate signed ICF for Part B of the study must be obtained by all the patients, prior to any data collection, irrespective of patients who are being enrolled from Part A of the study or who are being enrolled directly into Part B of the study.
6. Physician decision to treat patients with alpelisib plus fulvestrant, according to the prescribing label and the local practicing guidelines.
7. Patient should be alpelisib treatment naïve.

Exclusion Criteria:

PART A:

1\. Prior or current enrollment in any interventional clinical trial for ABC/MBC.

Part

PART B:

1. Patients' who had prior or current exposure to alpelisib or had prior or current exposure to any other PIK3CA inhibitor should be excluded.
2. Known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant.
3. Participant with type I or uncontrolled type II diabetes mellitus (HbA1c \>7, \[as per ADA/ACP guidelines 2020\]).
4. Participant has a history of severe cutaneous reactions like Stevens-Johnson-Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
5. Participant has documented pneumonitis/interstitial lung disease which is active and requiring treatment.
6. Participant with unresolved osteonecrosis of the jaw.
7. Participant reports history of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis, major surgery, any relevant medical condition, gastrointestinal (GI) condition preventing absorption, Child Pugh score B or C etc.